WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has shipped initial orders of ILUVIEN® to several U.K. National Health Service (NHS) facilities and the first NHS patient has received ILUVIEN for the treatment of chronic diabetic macular edema (DME) insufficiently responsive to available therapies.
Help employers find you! Check out all the jobs and post your resume.
